UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
8 out of 10 Korean doctors wish to leave the country
by Song Soo-youn
2019-06-04 15:28
[Special] Doctors skeptical about AI-based precision medicine ‘Dr. Answer’
by Kim Eun-young
2019-06-04 14:42
FDA OKs phase-1 trial for Yuhan’s investigational lung cancer drug
by Jeong Sae-im
2019-06-04 14:21
‘Indoor radon exposure raises tumor mutation in lung cancer patients’
by Park Gi-taek
2019-06-04 14:19
[ASCO 2019] ‘Ontruzant demonstrates equal quality to original drug’
by Lee Han-soo, KBR correspondent
2019-06-04 14:17
라인
‘New embolization technique can treat brain aneurysm’
by Kwak Sung-sun
2019-06-03 16:23
[ASCO 2019] ‘POLO study opens a new era for treating pancreatic cancer patients’
by Lee Han-soo, KBR corresponden
2019-06-03 16:18
Kolon’s minority shareholders demand over ₩25 billion in damage
by Jeong Sae-im
2019-06-03 14:53
Invossa inventor sold Kolon shares at highest value
by Jeong Sae-im
2019-06-03 14:52
[ASCO 2019]Novartis’ Kisqali aims to make comeback with new trial results
by Lee Han-soo, KBR correspondent
2019-06-03 13:41
라인
[Photo News]Scenes at ASCO 2019
by Lee Han-soo, KBR correspondent
2019-06-03 11:58
[ASCO 2019]Korea expanding presence in global oncology field
by Lee Han-soo, KBR correspondent
2019-06-03 11:17
[ASCO 2019]Roche CEO unveils his company’s future direction at ASCO 2019
by Lee Han-soo, KBR correspondent
2019-06-03 11:09
[ASCO 2019]'Asia vital region for Roche’
by Lee Han-soo, KBR correspondent
2019-06-03 11:01
Hanmi’s hypertension drug was effective in phase-4 study
by Jeong Sae-im
2019-05-31 16:05
라인
Until when will Kolon keep lying about Invossa?
by Jeong Sae-im
2019-05-31 14:59
Samsung BioLogics agrees to manufacture CytoDyn’s HIV drug
by Jeong Sae-im
2019-05-31 14:59
Will Seoul retrieve ₩14.7 billion invested in Invossa’s R&D?
by Kwak Sung-sun
2019-05-31 11:27
Supreme Court finalizes jail term to ‘Anaki’ operator
by Choi Gwang-seok
2019-05-30 16:36
AbbVie’s chronic lymphocytic leukemia drug wins Korean license
by Park Gi-taek
2019-05-30 15:14
-
이전
121
122
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top